Elan and Biogen Idec have restarted a safety trial of their multiple sclerosis drug Tysabri, which the companies recalled from the market after reports of rare brain infection were linked to the drug.
A US Food and Drug Administration panel earlier this month recommended the drug be returned to the market, with mandatory controls for risks and new cases of the fatal side effect, linked to two deaths. The companies expect a decision by the FDA by June 28.
Elan shares were up 28 cent to €12.10 in Dublin this evening.
